CRA analyzed market definition in antitrust litigation concerning a product in the non-opioid pain category. In defining the relevant antitrust market, our work accounted for indicators of competition among branded pharmaceutical products, including market positioning, factors driving physician choice, development of new approved indications, and competition for formulary listing.
Merger enforcement policies of the second Trump Administration: Early developments and priorities
In the article published by the American Bar Association (ABA), “Merger Enforcement Policies of the Second Trump Administration: Early Developments and...